Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — IPO Roadshow (March 2011)

32 slides from Aevi Genomic Medicine's IPO roadshow presentation, Mar 21, 2011

  1. Slide 1: Medgenics Investor Presentation

    INTERNAL (SE08TS Medgenics Investor Presentation

  2. Slide 2: Safe Harbor / Confidentiality Statement

    ed genics INTERNAL USE ONLY healing from within Safe Harbor / Confidentiality Statement: This presentation includes certain estimates and other forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to antici

  3. Slide 3: Summary

    edsenics Summary: INTERNAL USE ONLY healing from within = Med tech company focused on developing sustained, autologous protein therapies for chronic diseases. = Sustained protein production & delivery from patient’s own skin. = Designed to be better, safer and cheaper, replacing scores of injections

  4. Slide 4: Our Biopump method

    ed¢enics healing from within Our Biopump method: 1. Harvest the tissue by needle biopsy from under patient's skin. 2. Process tissue into a drug producing Biopump in 10-14 days by controlled transfer of desired gene. 3. Measure each Biopump’s continuous protein production level. 4. Implant required

  5. Slide 5: Biopump: Unique Platform, Disruptive Potential

    edgen ics INTERNAL USE ONLY healing from within Biopump: Unique Platform, Disruptive Potential: Platform for sustained production and delivery of therapeutic proteins using the patient’s own tissue. Current focus anemia, hepatitis C, hemophilia: = Biopumps routinely produce continuous EPO, IFN-a, FV

  6. Slide 6: Experienced Management Team

    edéenics healing from within Experienced Management Team: Extensive experience in healthcare industry, founded, operated and led firms to M&A totaling billions of dollars. Board of Directors: Andrew L. Pearlman PhD Pres/CEO >25yrs Biomed Eugene Bauer MD, Exec Chm. Former Dean, Stanford Med Sch, Conn

  7. Slide 7: Limitations of Current Therapeutic Protein Paradigm

    ed seni ics INTERNAL USE ONLY healing from within Limitations of Current Therapeutic Protein Paradigm: A Gene for Selected Protein "4 Protein Production in Mass Cell Culture E Delivery C Shipment = Limitations: = Complex & Very = Frequent, Painful «= All have Safety Concems Expensive Injections |S S

  8. Slide 8: Repeat Bolus Injections vs. Biopump

    . edgenics edgenics dgenics, healing from within Repeat Bolus Injections vs. Biopump: ies ; / | Injection overshoot - Adverse side effects concentration ‘ : ; in serum EPO: Cardiovascular Risk IFNa: Severe flu symptoms Therapeutic window Injection = undershoot Missed Injecti [5 Injected dose in rang

  9. Slide 9: How the Biopump Therapeutic System Works

    ed¢enics healing frem within How the Biopump Therapeutic System Works: a—Harvest dermis tissue (‘micro-organs’) from patient. b — Transfer to processing station. ¢— Adenoviral gutless vector carrying gene for desired protein d— Process each micro-organ into Biopump e—Biopump producing protein, f— Me

  10. Slide 10: Biopump Platform: EPODURE in vitro

    ed¢en ics INTERNAL USE ONLY healing frem within Biopump Platform: EPODURE in vitro: for anemia Sustained EPO high level production for 6+ mo 40000 EPODURE long term in vitro EPO secretion 1000 | Skin 1 m@Skin2 100 +} 1U/ Biopump / day. eo Sf 16 2 30 46 68 80 101 122 143 104 185 Time (Days) i Time to

  11. Slide 11: Biopump Platform: INFRADURE in vitro

    edgenics INTERNAL USE ONLY healing from within Biopump Platform: INFRADURE in vitro: for Hepatitis C Sustained IFNa high level production for 6+ mo. INFRADURE Long term in-vitro production 10000 a : 2 ae 4 te 27 37 48 62 76 97 118 139 160 181 202 223 244 Days from harvesting Time to th in Patient "

  12. Slide 12: EPODURE Replaces Injections, Elevates Hemoglobin Level

    edgenics INTERNAL USE ONLY healing from within EPODURE Replaces Injections, Elevates Hemoglobin Level >28 Months of Continuous Anemia Relief: Patient 2: Hb Levels [gm/dl] Days Following Administration 12 nS Ts [S|

  13. Slide 13: Biopump's Key Potential Healthcare Advantages

    ed¢gen ics INTERNAL USE ONLY healing from within Biopump’s Key Potential Healthcare Advantages: Increased efficacy: = Sustained dose within therapeutic window. Improved safety: = Patient's own protein - not produced in rodent cells. = Fewer side effects resulting from overdose. Improved patient comp

  14. Slide 14: Market Opportunity

    Aed cen ics INTERNAL USE ONLY healing from within Market Opportunity: Clear value proposition. Worldwide market for protein therapy projected 2013 to exceed $132 billion: 3 areas of initial focus: Addressing the needs of millions of patients With protein sales over $16 billion in 2009: Anemia Hepati

  15. Slide 15: Pipeline for Biopump platform

    edgenics healing frem within INTERNAL USE ONLY Pipeline for Biopump platform: Anemia Erythropoetin Hepatitis C Interferon Alpha Hemophilia Factor Vill Growth Retardation Growth hormone Multiple Sclerosis Interferon Beta Diabetes Insulin Arthritis IL-1Ra Wound Healing PDGF-BB Obesity Peptide YY3-36 C

  16. Slide 16: Value proposition

    edgenics Value proposition: healing from within INTERNAL USE ONLY Game Changer - Potential major win for: Patients Physicians Payors Pharma Partner - Replaces frequent - Billable procedure + Reduces costs + Blockbuster opportunities injectors - Improved patient flow = Fewer claims = No $B Protein g

  17. Slide 17: Business Strategy: One Platform, Multiple Alliances

    edgen ics INTERNAL USE ONLY healing from within Business Strategy: One Platform > Multiple Alliances: Business Model - Revenues before product approval. Platform: Same low cost core tech - multiple deal opportunities. Major Opportunities: Each >$1B/year, no protein factory needed. Other Opportunitie

  18. Slide 18: Recent Protein Therapy Licensing Deal

    ed¢en ics INTERNAL USE ONLY healing from within *Recent Protein Therapy Licensing Deal: Bristol Meyers Squibb & ZymoGenetics, $535m deal, at Phase Ib Jan 2009 = BMS gets global rights to ZymoGenetics’ hepatitis C program led by IL29 (interferon lambda) in Phase lb. = Potential pre-sales deal value:

  19. Slide 19: Valuation metrics - Recent Comparables

    edgenics healing from within INTERNAL USE ONLY Valuation metrics - Recent Comparables: Licensing Deals Companies PROLOR gerzyme & MERCK PROLOR Osiris ‘Lpath | AMEX: PBTH Ph Ill Deal = $4.28 Ph | Deal = $422M Cap $317M entering Ph Il Nov 2008 May 2010 Feb 2011 ari ae ods PROTALDX + + Blotherapeutics

  20. Slide 20: Our First Commercial Validation Deal - Baxter/Hemophilia

    edgen ics INTERNAL USE ONLY healing from within Our First Commercial Validation Deal - Baxter/Hemophilia: = Baxter: Market leader in Hemophilia signed a feasibility and option agreement with Medgenics in Oct 2009. = Feasibility Deal: Development of a Biopump producing clotting protein Factor VIII fo

  21. Slide 21: Lead Products

    ed genics Lead Products TERNAL UsE ONLY healing from within = EPODURE (anemia) Sustained EPO therapy ($9.6B/yr) could replace $15-30,000/yr/patient in injections, offering: = Superior treatment at lower cost: > 6-12 months sustained EPO therapy, avoid peak overdose risks, improve compliance and reli

  22. Slide 22: Hemoglobin Cycling with EPO Injections vs. EPODURE Response

    edgenics INTERNAL USE ONLY healing from within Hemoglobin Cycling with EPO Injections vs. EPODURE Response: Patient 3: Hb Levels [gm/dl] -600 -500 400 -300 -200 -100 0 100 Days Following Administration 2 aay ew | eee | |

  23. Slide 23: EPO Naive - Hemoglobin response

    edgenics INTERNAL USE ONLY healing from within EPO Naive - Hemoglobin response: Patient 4: Hb Levels [gm/dl] 60 -40 -20 0 20 40 60 80 100 120 140 160 180 200 220 240 Days Following Administration Say Se | (ey [| || 2

  24. Slide 24: EPODURE mid-dose Sustained Hemoglobin response

    ed gen ics INTERNAL USE ONLY healing from within EPODURE mid-dose Sustained Hemoglobin response: Patient 13: Hb Levels [gm/dl] 13 | . -40 -20 0 20 40 60 Days Following Administration 80 Summary Opportunity | Biopump | sirategy | Team | Products | implementation | clinical | other | m4

  25. Slide 25: Phase I/II Study Conclusions

    ed¢en ics INTERNAL USE ONLY healing frem within Phase I/II Study Conclusions Presented at ASN Nov 2010 by leading authority* = EPODURE is safe and doseable; no antigenic response. = Clinical feasibility demonstrated. = Single EPODURE administration can raise and maintain hemoglobin levels for up to

  26. Slide 26: IP Protection & Practical Application

    W| edgenics INTERNAL USE ONLY healing from within IP Protection & Practical Application: = 10 issued patents, over 50 pending patents. = Licenses have been acquired for Biopump and related key elements: = FVIII license from Univ of Michigan. = Freedom to Operate: off-patent proteins or use of cDNA.

  27. Slide 27: Regional Implementation

    edgenics healing from within Regional Implementation: Multiple Processing Stations: control parameters of temp, gases, agitation, ete Transport from Harvesting Center Medium Sample Removal Biopump Secretion and Release Criteria Analysis Transport to Treatment Center (up to 3+ days) Local cryo-storag

  28. Slide 28: Route to Revenues, Products

    ed¢en ics INTERNAL USE ONLY healing from within Route to Revenues, Products: Regulatory: = Safety already shown, clear route forward. = QA designed in: automated processor using sealed cassettes. = Niche: expedited route, small pivotal trial for approval. Clinical Pathway Simplified: = Delivers well

  29. Slide 29: Key Milestones

    ed¢gen ics INTERNAL USE ONLY healing from within Key 12 month Milestones: EPODURE: Complete Phase I/II trial; seek IND for Phase IIB, other pre-trial preparations for launch in renal anemia. INFRADURE: prepare, launch, obtain initial data Phase I/II trial in Hepatitis C. HEMODURE: Improve FVIII prod

  30. Slide 30: Investment Highlights & Conclusions

    ed¢éen ics INTERNAL USE ONLY healing from within Investment Highlights & Conclusions: * Disruptive Platform Technology for > $132B Protein Market. = Potentially better, safer and less costly. = Strong IP Portfolio and value proposition. = Lead Products focusing on $16B in Anemia (EPODURE) Hepatitis

  31. Slide 31: Offering Summary

    edgenics Offering Summary: healing from within INTERNAL USE ONLY Offering Size $15 million Over-Allotment Option 15% Initial Price Range $5.00 to $7.00 per share of common stock and 0.25 warrant Use of Proceeds Clinical Trials EPODURE and INFRADURE Product Development & Business Development General

  32. Slide 32: Thank You

    INTERNAL EST CES: THANK YOU 44 ent and CEO

Medgenics — IPO Roadshow (March 2011) on 6ix